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The bisphosphonate study is an international collaboration between the NASA and JAXA space agencies to 
investigate the potential value of antiresorptive drugs to mitigate the well-established bone changes associated with 
long-duration spaceflight. Our hypothesis is that an antiresorptive drug in combination with in-flight exercise will 
ameliorate bone loss and hypercalcuria during long-duration spaceflight. We have completed data analysis for 7 
crewmembers treated with alendronate during flight and 3 of 10 controls without treatment. We previously reported 
the pre/postflight changes in bone density and the pre versus in-flight changes in various biomarkers in 
crewmembers taking alendronate during flight. The purpose of this report is to compare these results with the 12-
month follow-up data. The table below presents these data as a percentage change from baseline either immediately 
postflight or in-flight (biochemical markers) with a 1-year follow-up. 
 
 Changes in Alendronate Treated Subjects (n=7); % 
Change from Baseline (mean ± SD) 
 R+<2 week R+1 year 
DXA BMD   
Total Hip -0.2 ± 1.5 0.8 ± 1.4 
Trochanter 0.02 ± 2.3 2.1 ± 1.2* 
Femur Neck -0.7 ± 1.2  1.5 ± 1.7*  
Lumbar Spine 2.8 ± 4.0 3.9 ± 3.8* 
QCT BMD   
Trabecular Total Hip  -1.1 ± 9.8 -1.1 ± 12.1 
Cortical Total Hip  -0.6 ± 4.7 -2.9 ± 3.7 
Trabecular Trochanter -1.9 ± 9.9 -1.2 ± 12.4 
Cortical Trochanter -0.5 ± 5.0 -3.2 ± 4.3 
Trabecular Femur Neck 6.5 ± 14.8 2.8 ± 7.2 
Cortical Femur Neck -1.0 ± 4.8 -3.9 ± 3.1* 
Hip Strength   
Fall -0.1 ± 7.6 -4.9 ± 4.8   
Standing 0.80 ± 10.1 -2.2 ± 4.9 
   
 In Flight R+1 year 
Resorption Markers   
Urinary NTX -25.8 ± 30.1* -29.3 ± 29.3* 
Serum CTX-ß -4.8 ± 32.7 25.9 ± 102 
Formation Markers   
BSAP -15.0 ± 11.5 6.9 ± 34.0 
Osteocalcin 1.6 ± 45.0 -8.7 ± 50.3 
Urinary Ca -17.5 ± 19.4 -2.9 ± 37.5 
25(OH) Vit D -13.5 ± 10.5 5.5 ± 37.8 
1,25(OH)2 Vit D 9.8 ± 60.5 -3.7 ± 48.6 
Intact PTH 35.9 ± 25.1* 6.7 ± 14.8 
Abbreviations: NTX=N-terminal telopeptide, CTXB=C-terminal telopeptide, BSAP=Bone Specific  
Alkaline Phosphatase, PTH=Parathyroid hormone. *P < 0.05 
 
These results indicate that the use of an antiresorptive plus exercise may be effective during long-duration 
spaceflight (previously reported: Osteoporosis Int. 24:2105–2114, 2013) and that bone measures at 1 year remain at 
or near baseline values.  
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